Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

We report the generation of a chimeric monoclonal antibody (ch806) with specificity for an epitope on the epidermal growth factor receptor (EGFR) that is different from that targeted by all other anti-EGFR therapies. Ch806 antibody is reactive to both de2-7 and overexpressed wild-type (wt) EGFR but...

Descripción completa

Detalles Bibliográficos
Autores principales: Panousis, C, Rayzman, V M, Johns, T G, Renner, C, Liu, Z, Cartwright, G, Lee, F-T, Wang, D, Gan, H, Cao, D, Kypridis, A, Smyth, F E, Brechbiel, M W, Burgess, A W, Old, L J, Scott, A M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361945/
https://www.ncbi.nlm.nih.gov/pubmed/15770208
http://dx.doi.org/10.1038/sj.bjc.6602470

Ejemplares similares

Ejemplares similares